Free Trial
NASDAQ:ATRC

AtriCure (ATRC) Stock Price, News & Analysis

AtriCure logo
$30.72 -1.34 (-4.18%)
Closing price 07/11/2025 04:00 PM Eastern
Extended Trading
$30.73 +0.01 (+0.03%)
As of 07/11/2025 04:20 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

About AtriCure Stock (NASDAQ:ATRC)

Key Stats

Today's Range
$30.49
$31.89
50-Day Range
$29.07
$34.94
52-Week Range
$20.20
$43.11
Volume
388,102 shs
Average Volume
593,727 shs
Market Capitalization
$1.52 billion
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$50.67
Consensus Rating
Buy

Company Overview

AtriCure Stock Analysis - MarketRank™

See Top-Rated MarketRank™ Stocks
62nd Percentile Overall Score

ATRC MarketRank™: 

AtriCure scored higher than 62% of companies evaluated by MarketBeat, and ranked 382nd out of 944 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

  • Consensus Rating

    AtriCure has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 9 buy ratings, no hold ratings, and no sell ratings.

  • Amount of Analyst Coverage

    AtriCure has only been the subject of 3 research reports in the past 90 days.

  • Read more about AtriCure's stock forecast and price target.
  • Earnings Growth

    Earnings for AtriCure are expected to grow in the coming year, from ($0.60) to ($0.46) per share.

  • Price to Earnings Ratio vs. the Market

    The P/E ratio of AtriCure is -37.93, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

  • Price to Earnings Ratio vs. Sector

    The P/E ratio of AtriCure is -37.93, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

  • Price to Book Value per Share Ratio

    AtriCure has a P/B Ratio of 3.25. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.

  • Read more about AtriCure's valuation and earnings.
  • Percentage of Shares Shorted

    3.24% of the float of AtriCure has been sold short.
  • Short Interest Ratio / Days to Cover

    AtriCure has a short interest ratio ("days to cover") of 2.8, which is generally considered an acceptable ratio of short interest to trading volume.
  • Change versus previous month

    Short interest in AtriCure has recently decreased by 0.64%, indicating that investor sentiment is improving.
  • Dividend Yield

    AtriCure does not currently pay a dividend.

  • Dividend Growth

    AtriCure does not have a long track record of dividend growth.

  • Percentage of Shares Shorted

    3.24% of the float of AtriCure has been sold short.
  • Short Interest Ratio / Days to Cover

    AtriCure has a short interest ratio ("days to cover") of 2.8, which is generally considered an acceptable ratio of short interest to trading volume.
  • Change versus previous month

    Short interest in AtriCure has recently decreased by 0.64%, indicating that investor sentiment is improving.
  • News Sentiment

    AtriCure has a news sentiment score of 0.47. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 1.00 average news sentiment score of Medical companies.
  • News Coverage This Week

    MarketBeat has tracked 4 news articles for AtriCure this week, compared to 5 articles on an average week.
  • MarketBeat Follows

    2 people have added AtriCure to their MarketBeat watchlist in the last 30 days.
  • Insider Buying vs. Insider Selling

    In the past three months, AtriCure insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $83,600.00 in company stock.

  • Percentage Held by Insiders

    Only 3.50% of the stock of AtriCure is held by insiders.

  • Percentage Held by Institutions

    99.11% of the stock of AtriCure is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

  • Read more about AtriCure's insider trading history.
Receive ATRC Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for AtriCure and its competitors with MarketBeat's FREE daily newsletter.

ATRC Stock News Headlines

This Cold War “Accident” Could Unleash New $100 Trillion AI Boom
Obscure Metal More Valuable than Gold and Bitcoin… COMBINED? This strange "AI Metal" holds the key to the $100 trillion AI boom. Which is why Jeff Brown recently traveled to a location that has one of the highest concentrations of this metal in the world. And you won't believe what he uncovered.
AtriCure, Inc. (ATRC) - Yahoo Finance
See More Headlines

ATRC Stock Analysis - Frequently Asked Questions

AtriCure's stock was trading at $30.56 at the start of the year. Since then, ATRC stock has increased by 0.5% and is now trading at $30.72.

AtriCure, Inc. (NASDAQ:ATRC) released its quarterly earnings results on Tuesday, April, 29th. The medical device company reported ($0.14) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.25) by $0.11. The business's revenue was up 13.5% on a year-over-year basis.
Read the conference call transcript
.

AtriCure subsidiaries include SentreHEART.

AtriCure's top institutional investors include Assenagon Asset Management S.A. (0.09%), Harbor Capital Advisors Inc. (0.05%) and First Bank & Trust (0.02%). Insiders that own company stock include Salvatore Privitera, Vinayak Doraiswamy, Justin J Noznesky, Karl S Dahlquist, Karen Prange and Maggie Yuen.
View institutional ownership trends
.

Shares of ATRC stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

Based on aggregate information from My MarketBeat watchlists, some other companies that AtriCure investors own include Meta Platforms (META), NVIDIA (NVDA), JPMorgan Chase & Co. (JPM), Tesla (TSLA), Advanced Micro Devices (AMD), Visa (V) and Home Depot (HD).

Company Calendar

Last Earnings
4/29/2025
Today
7/12/2025
Next Earnings (Estimated)
7/29/2025
Fiscal Year End
12/31/2025

Industry, Sector and Symbol

Stock Exchange
NASDAQ
Sector
Medical
Industry
MED PRODUCTS
Sub-Industry
Health Care Equipment
Current Symbol
NASDAQ:ATRC
CIK
1323885
Employees
1,300
Year Founded
2000

Price Target and Rating

High Price Target
$60.00
Low Price Target
$44.00
Potential Upside/Downside
+64.9%
Consensus Rating
Buy
Rating Score (0-4)
3.00
Research Coverage
9 Analysts

Profitability

EPS (Trailing Twelve Months)
($0.81)
Trailing P/E Ratio
N/A
Forward P/E Ratio
N/A
P/E Growth
N/A
Net Income
-$44.70 million
Net Margins
-7.95%
Pretax Margin
-7.73%
Return on Equity
-5.68%
Return on Assets
-4.34%

Debt

Debt-to-Equity Ratio
0.16
Current Ratio
4.11
Quick Ratio
2.88

Sales & Book Value

Annual Sales
$465.31 million
Price / Sales
3.27
Cash Flow
N/A
Price / Cash Flow
N/A
Book Value
$9.46 per share
Price / Book
3.25

Miscellaneous

Outstanding Shares
49,510,000
Free Float
47,772,000
Market Cap
$1.52 billion
Optionable
Optionable
Beta
1.56

Social Links

The 10 Best AI Stocks to Own in 2025 Cover

Wondering where to start (or end) with AI stocks? These 10 simple stocks can help investors build long-term wealth as artificial intelligence continues to grow into the future.

Get This Free Report

This page (NASDAQ:ATRC) was last updated on 7/12/2025 by MarketBeat.com Staff
From Our Partners